<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537173</url>
  </required_header>
  <id_info>
    <org_study_id>HOG COE-02</org_study_id>
    <secondary_id>DoD Grant BC030400</secondary_id>
    <nct_id>NCT00537173</nct_id>
  </id_info>
  <brief_title>Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer</brief_title>
  <official_title>Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial provides a unique opportunity in that it combines genomic, proteomic and&#xD;
      pharmacogenomic assessments in patients receiving chemotherapy for advanced breast cancer. To&#xD;
      date no other trials have analyzed gene and protein expression at the same time points in the&#xD;
      same patient, combined with clinical outcome. Similar to previous attempts to predict&#xD;
      response based on expression of a single gene or protein, we expect that neither genomic or&#xD;
      proteomic profiling alone will be sufficient to optimize therapy. Rather, we expect an&#xD;
      iterative process that combines information gleaned from both platforms, modified to avoid&#xD;
      toxicity based on pharmacogenomics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.&#xD;
&#xD;
      Sample Collection:&#xD;
&#xD;
        -  Core biopsy&#xD;
&#xD;
        -  Blood sample&#xD;
&#xD;
           28-day Cycle Treatment Regimen:&#xD;
&#xD;
        -  Paclitaxel 90 mg/m2 IV D1, 8, and 15&#xD;
&#xD;
        -  Avastin 10 mg/kg IV D1 and 15&#xD;
&#xD;
      ECOG Performance Status of 0 or 1&#xD;
&#xD;
      Life Expectancy: Not specified&#xD;
&#xD;
      Hematopoietic:&#xD;
&#xD;
        -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
        -  Absolute neutrophil count &gt; 1200/mm³&#xD;
&#xD;
        -  PTT &lt; 1.5 x upper limit of normal&#xD;
&#xD;
        -  INR &lt; 1.5 x upper limit of normal&#xD;
&#xD;
      Hepatic:&#xD;
&#xD;
        -  Total bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
        -  SGOT (AST) &lt; 2 x upper limit of normal&#xD;
&#xD;
      Renal: Not specified&#xD;
&#xD;
      Cardiovascular:&#xD;
&#xD;
        -  Clinically significant cardiovascular or cerebrovascular disease including prior&#xD;
           myocardial infarction (within 6 months prior to study entry), unstable angina, Grade II&#xD;
           or greater peripheral vascular disease, New York Heart Association (NYHA) Grade II or&#xD;
           greater congestive heart failure, hypertensive crises, hypertensive encephalopathy or&#xD;
           uncontrolled hypertension (SBP&gt;150, DBP&gt;100).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of Accrual&#xD;
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To correlate tumor gene expression (genomic profile) with response to paclitaxel + Avastin in patients with advanced breast cancer</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To correlate serum and tumor proteomic profiles with response; To compare serum and tissue proteomic analyses; To compare genomic and proteomic profiles; To correlate toxicity and/or response with drug-specific pharmacogenomic parameters.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">11</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <description>Paclitaxel 90 mg/m2 IV D1, 8, and 15 + Avastin 10 mg/kg IV, day 1 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Core Biopsy</intervention_name>
    <description>biopsy</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Collection</intervention_name>
    <description>Blood/serum sample</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 90 mg/m2 IV, day 1, 8 and 15</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>Avastin 10 mg/kg IV, day 1 and 15</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and tumor samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population is limited to patients with advanced breast cancer who are receiving&#xD;
        paclitaxel + Avastin&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the breast with measurable&#xD;
             locally recurrent, locally advanced (that is not amenable to resection with curative&#xD;
             intent), or metastatic disease.&#xD;
&#xD;
          -  Patients must consent to have a biopsy performed to obtain fresh tissue or be able to&#xD;
             identify a FFPE tissue block in which tissue samples can be obtained to complete the&#xD;
             testing for this study.&#xD;
&#xD;
          -  Planned chemotherapy regimen of paclitaxel and Avastin for the treatment of metastatic&#xD;
             breast cancer.&#xD;
&#xD;
          -  Females age &gt; 18 years&#xD;
&#xD;
          -  Written informed consent and HIPAA authorization for release of personal health&#xD;
             information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must not have had chemotherapy for locally recurrent or metastatic breast&#xD;
             cancer.&#xD;
&#xD;
          -  Hormonal therapy for locally recurrent or metastatic disease must have been&#xD;
             discontinued at least 2 weeks prior to study entry.&#xD;
&#xD;
          -  Patients must not have had adjuvant or neoadjuvant taxane therapy within 12 months&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Breast cancer overexpressing HER-2 (gene amplification by FISH or 3+ overexpression by&#xD;
             immunohistochemistry) are not eligible unless they have received prior therapy with&#xD;
             Herceptin.&#xD;
&#xD;
          -  Patients must not have had a major surgical procedure within 4 weeks prior to study&#xD;
             entry. (Placement of vascular access device, and breast biopsy, will not be considered&#xD;
             major surgery.)&#xD;
&#xD;
          -  Patients must not have had a minor surgical procedure, placement of an access device,&#xD;
             or fine needle aspiration within 7 days of starting protocol therapy.&#xD;
&#xD;
          -  Patients must not have had radiation within 2 weeks prior to study entry.&#xD;
&#xD;
          -  Previously radiated area(s) must not be the only site of disease for study entry.&#xD;
&#xD;
          -  Patients must not have a history of bleeding diathesis or have used anticoagulant&#xD;
             therapy within 10 days of study entry. (Low dose anticoagulant therapy to maintain&#xD;
             patency of a vascular access device is allowed.)&#xD;
&#xD;
          -  Patients with a history of deep vein thrombosis or pulmonary embolism are not&#xD;
             eligible.&#xD;
&#xD;
          -  Aspirin usage (&gt; 325 mg/day) or other nonsteroidal anti-inflammatory medications known&#xD;
             to inhibit platelet function daily are not allowed within 10 days prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Patients currently using any of the following drugs known to inhibit platelet function&#xD;
             are not eligible: dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel&#xD;
             (Plavix) and cilostazol (Pletal).&#xD;
&#xD;
          -  Patients must not have a history of TIA or CVA within 6 months prior to study entry.&#xD;
&#xD;
          -  Patients must not have a history or radiologic evidence of CNS metastases including&#xD;
             previously treated, resected or asymptomatic brain lesions or leptomeningeal&#xD;
             involvement (head CT or MRI must be obtained within 6 weeks prior to study entry).&#xD;
&#xD;
          -  Patients must not have a non-healing wound or fracture.&#xD;
&#xD;
          -  Patients must not have a hypersensitivity to paclitaxel or drugs using the vehicle&#xD;
             Cremophor, Chinese hamster ovary cell products or other recombinant human antibodies.&#xD;
&#xD;
          -  Females must not be pregnant or breastfeeding. Females of childbearing potential must&#xD;
             use an accepted and effective method of contraception (hormonal or barrier method of&#xD;
             birth control; abstinence) while on treatment and for a 3 month period thereafter.&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test within 7 days&#xD;
             prior to being registered for protocol therapy. Subjects are considered not of child&#xD;
             bearing potential if they are surgically sterile (they have undergone a hysterectomy,&#xD;
             bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to study entry&#xD;
&#xD;
          -  Urine protein: creatinine (UPC) ratio &gt; 1.0 at baseline or urine protein dipstick &gt;&#xD;
             2+.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Sledge, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoosier Oncology Group, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Care Center of Southern Indiana</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Center</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Methodist Breast Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hoosieroncologygroup.org</url>
    <description>Hoosier Oncology Group Home Page</description>
  </link>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>September 26, 2007</study_first_submitted>
  <study_first_submitted_qc>September 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2007</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <name_title>Kathy Miller, M.D.</name_title>
    <organization>Hoosier Oncology Group</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

